FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2276933751> ?p ?o ?g. }

• W2276933751 endingPage "1288" @default.
• W2276933751 startingPage "1283" @default.
• W2276933751 abstract "Background Fetal tachyarrhythmia can lead to fetal hydrops due to heart failure. Flecainide is often considered as second-line therapy when digoxin monotherapy fails, which is more likely in hydropic fetuses. Time to conversion to sinus rhythm (SR) is critical in cases presenting with hydrops. Objective The aim of this study was to evaluate the efficacy and time to conversion to SR of transplacental treatment, especially flecainide. Methods This is a retrospective observational study of 46 fetuses with fetal tachyarrhythmia. Treatment was either flecainide (n = 28, 60.9%), digoxin+flecainide combination (n = 4, 8.7%), or digoxin (n = 10, 21.7%). In 4 fetuses (8.7%), no treatment was necessary. Results In our study population, 26 of the 32 fetuses (81.2%) that were treated with flecainide as a first-line therapy (flecainide or digoxin+flecainide) converted to SR. The median time to conversion to SR was 3 days (range 1–7 days) with flecainide monotherapy and 11.5 days (range 3–14 days) with a combination therapy. Seventy-two percent (13/18) of hydropic fetuses and 90% (9/10) of nonhydropic fetuses converted to SR when treated with flecainide monotherapy. There was no statistical difference in rates of conversion to SR in hydropic and nonhydropic fetuses (P = .37) or time to conversion to SR in the 2 groups (P = .9). In the majority of the remaining fetuses, there was a partial response with decreased ventricular heart rates that were well tolerated. Conclusion Flecainide is highly effective in achieving SR in hydropic and nonhydropic fetuses with supraventricular tachycardia in a median time of 3 days. In our opinion, flecainide should be considered as first-line therapy in fetal supraventricular tachycardia with and without hydrops. Fetal tachyarrhythmia can lead to fetal hydrops due to heart failure. Flecainide is often considered as second-line therapy when digoxin monotherapy fails, which is more likely in hydropic fetuses. Time to conversion to sinus rhythm (SR) is critical in cases presenting with hydrops. The aim of this study was to evaluate the efficacy and time to conversion to SR of transplacental treatment, especially flecainide. This is a retrospective observational study of 46 fetuses with fetal tachyarrhythmia. Treatment was either flecainide (n = 28, 60.9%), digoxin+flecainide combination (n = 4, 8.7%), or digoxin (n = 10, 21.7%). In 4 fetuses (8.7%), no treatment was necessary. In our study population, 26 of the 32 fetuses (81.2%) that were treated with flecainide as a first-line therapy (flecainide or digoxin+flecainide) converted to SR. The median time to conversion to SR was 3 days (range 1–7 days) with flecainide monotherapy and 11.5 days (range 3–14 days) with a combination therapy. Seventy-two percent (13/18) of hydropic fetuses and 90% (9/10) of nonhydropic fetuses converted to SR when treated with flecainide monotherapy. There was no statistical difference in rates of conversion to SR in hydropic and nonhydropic fetuses (P = .37) or time to conversion to SR in the 2 groups (P = .9). In the majority of the remaining fetuses, there was a partial response with decreased ventricular heart rates that were well tolerated. Flecainide is highly effective in achieving SR in hydropic and nonhydropic fetuses with supraventricular tachycardia in a median time of 3 days. In our opinion, flecainide should be considered as first-line therapy in fetal supraventricular tachycardia with and without hydrops." @default.
• W2276933751 created "2016-06-24" @default.
• W2276933751 creator A5005750229 @default.
• W2276933751 creator A5016717514 @default.
• W2276933751 creator A5022064158 @default.
• W2276933751 creator A5037489880 @default.
• W2276933751 creator A5048541901 @default.
• W2276933751 creator A5079690554 @default.
• W2276933751 date "2016-06-01" @default.
• W2276933751 modified "2023-09-23" @default.
• W2276933751 title "High-dose flecainide is the most effective treatment of fetal supraventricular tachycardia" @default.
• W2276933751 cites W1966813048 @default.
• W2276933751 cites W1979686488 @default.
• W2276933751 cites W1984499018 @default.
• W2276933751 cites W1991619226 @default.
• W2276933751 cites W2006616530 @default.
• W2276933751 cites W2009562355 @default.
• W2276933751 cites W2015803351 @default.
• W2276933751 cites W2051492244 @default.
• W2276933751 cites W2070198389 @default.
• W2276933751 cites W2084782958 @default.
• W2276933751 cites W2096612114 @default.
• W2276933751 cites W2099183219 @default.
• W2276933751 cites W2101616031 @default.
• W2276933751 cites W2101718013 @default.
• W2276933751 cites W2112218762 @default.
• W2276933751 cites W2119134829 @default.
• W2276933751 cites W2163835693 @default.
• W2276933751 cites W2413102425 @default.
• W2276933751 cites W4244573433 @default.
• W2276933751 doi "https://doi.org/10.1016/j.hrthm.2016.01.029" @default.
• W2276933751 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26829115" @default.
• W2276933751 hasPublicationYear "2016" @default.
• W2276933751 type Work @default.
• W2276933751 sameAs 2276933751 @default.
• W2276933751 citedByCount "39" @default.
• W2276933751 countsByYear W22769337512016 @default.
• W2276933751 countsByYear W22769337512017 @default.
• W2276933751 countsByYear W22769337512018 @default.
• W2276933751 countsByYear W22769337512019 @default.
• W2276933751 countsByYear W22769337512020 @default.
• W2276933751 countsByYear W22769337512021 @default.
• W2276933751 countsByYear W22769337512022 @default.
• W2276933751 countsByYear W22769337512023 @default.
• W2276933751 crossrefType "journal-article" @default.
• W2276933751 hasAuthorship W2276933751A5005750229 @default.
• W2276933751 hasAuthorship W2276933751A5016717514 @default.
• W2276933751 hasAuthorship W2276933751A5022064158 @default.
• W2276933751 hasAuthorship W2276933751A5037489880 @default.
• W2276933751 hasAuthorship W2276933751A5048541901 @default.
• W2276933751 hasAuthorship W2276933751A5079690554 @default.
• W2276933751 hasConcept C126322002 @default.
• W2276933751 hasConcept C164705383 @default.
• W2276933751 hasConcept C172680121 @default.
• W2276933751 hasConcept C2775914520 @default.
• W2276933751 hasConcept C2776934708 @default.
• W2276933751 hasConcept C2776953305 @default.
• W2276933751 hasConcept C2777707475 @default.
• W2276933751 hasConcept C2778198053 @default.
• W2276933751 hasConcept C2779161974 @default.
• W2276933751 hasConcept C2779234561 @default.
• W2276933751 hasConcept C2779837460 @default.
• W2276933751 hasConcept C2779906218 @default.
• W2276933751 hasConcept C2780283014 @default.
• W2276933751 hasConcept C42219234 @default.
• W2276933751 hasConcept C54355233 @default.
• W2276933751 hasConcept C71924100 @default.
• W2276933751 hasConcept C86803240 @default.
• W2276933751 hasConceptScore W2276933751C126322002 @default.
• W2276933751 hasConceptScore W2276933751C164705383 @default.
• W2276933751 hasConceptScore W2276933751C172680121 @default.
• W2276933751 hasConceptScore W2276933751C2775914520 @default.
• W2276933751 hasConceptScore W2276933751C2776934708 @default.
• W2276933751 hasConceptScore W2276933751C2776953305 @default.
• W2276933751 hasConceptScore W2276933751C2777707475 @default.
• W2276933751 hasConceptScore W2276933751C2778198053 @default.
• W2276933751 hasConceptScore W2276933751C2779161974 @default.
• W2276933751 hasConceptScore W2276933751C2779234561 @default.
• W2276933751 hasConceptScore W2276933751C2779837460 @default.
• W2276933751 hasConceptScore W2276933751C2779906218 @default.
• W2276933751 hasConceptScore W2276933751C2780283014 @default.
• W2276933751 hasConceptScore W2276933751C42219234 @default.
• W2276933751 hasConceptScore W2276933751C54355233 @default.
• W2276933751 hasConceptScore W2276933751C71924100 @default.
• W2276933751 hasConceptScore W2276933751C86803240 @default.
• W2276933751 hasIssue "6" @default.
• W2276933751 hasLocation W22769337511 @default.
• W2276933751 hasLocation W22769337512 @default.
• W2276933751 hasOpenAccess W2276933751 @default.
• W2276933751 hasPrimaryLocation W22769337511 @default.
• W2276933751 hasRelatedWork W1965319863 @default.
• W2276933751 hasRelatedWork W1980936991 @default.
• W2276933751 hasRelatedWork W20738851 @default.
• W2276933751 hasRelatedWork W2092675591 @default.
• W2276933751 hasRelatedWork W2101718013 @default.
• W2276933751 hasRelatedWork W2420288082 @default.
• W2276933751 hasRelatedWork W2514767098 @default.
• W2276933751 hasRelatedWork W2745503502 @default.

• next